I

IRIS Research and Development | Plantation, FL

Research site
(Unclaimed)
Location
140 SW 84th Avenue, Suite B, Plantation, Florida, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

12 of 26
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Bas...

Enrolling
Diffuse Cutaneous Systemic Sclerosis
Sclerosis, Systemic
Drug: HZN-825 BID
Drug: HZN-825 QD

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Risankizumab
Biological: Placebo

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Risankizumab
Biological: Placebo

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Enrolling
Systemic Lupus Erythematosus
Drug: Afimetoran
Other: Placebo

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Enrolling
Scleroderma, Systemic
Drug: Placebo
Drug: Avenciguat (BI 685509)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Active, not recruiting
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Enrolling
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroi...

Active, not recruiting
Giant Cell Arteritis (GCA)
Drug: Upadacitinib
Other: Placebo

Primary Objectives:The primary efficacy objective is to assess the efficacy of 52 weeks of open-label treatment with HZN-825 in participants with dif...

Invitation-only
Diffuse Cutaneous Systemic Sclerosis
Sclerosis, Systemic
Drug: HZN-825

The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the...

Active, not recruiting
Rheumatoid Arthritis
Drug: Filgotinib
Drug: Placebo to match filgotinib
Locations recently updated

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderat...

Active, not recruiting
Rheumatoid Arthritis
Procedure: Implant Procedure
Drug: Conventional Synthetic DMARD

Trial conditions

Arthritis (9 trials)
Systemic Lupus Erythemat... (9 trials)
Rheumatoid Arthritis (6 trials)
Diffuse Scleroderma (3 trials)
Psoriatic Arthritis (3 trials)
Sclerosis (3 trials)
Systemic Scleroderma (3 trials)
Gout (2 trials)
Arteritis (1 trial)
Giant Cell Arteritis (1 trial)

And 5 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems